Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

C-Peptide (U-type) Mouse ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Species:Mouse
Please select your region to see available products and prices.
Cat. No. Size Price


RSHAKRCP031R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Cell culture medium

Sample Requirements

10 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

30–3 000 pg/ml

Limit of Detection

1.5 pg/ml

Summary

Research topic

Animal studies, Diabetology - Insulin, C-Peptide, Proinsulin

Summary

Insulin is first synthesized as a single chain polypeptide, proinsulin, then three disulfide bonds are formed, and finally divided into insulin and C-peptide through enzymatic splitting. Mouse C-peptide 1 is a single chain peptide composed of 29 amino acids, while C-peptide 2 is composed of 31 residues. C-peptide is secreted together with insulin. The role of C-peptide has been considered to keep the best configuration to form three disulfide bonds, and has no biological activity, however, recent studies revealed that C-peptide can bind, probably, a G-proteincoupling specific receptor present on the surface of endothelial cells, kidney microtubule cells and fibroblasts, resulting in activation of calcium-dependent intracellular signaling, activation of Na+-K+-ATPase, and enhancement of NO synthesis. Administration of C-peptide to DM1 patients enhances blood circulation in the skeletal muscle and skin, and also minimizes kidney glomerular hyperfiltration, decreasing albumin excretion into urine, and also improves nervous function, indicating that C-peptide should be given together with insulin to DM1 patients. Important region to bind receptor has been reported to be C-terminal pentapeptide (27-31).
The biological half life of C-peptide is several times longer than that of insulin. Measurement of C-peptide is useful in estimation of pancreatic function for insulin synthesis and secretion. Urinary C-peptide concentration is well correlated to its blood level. C-peptide measurement is also useful in estimation of insulin secretion by cultured islet of Langerhans because very often insulin is added to the culture medium, and it is difficult to discriminate secreted insulin from added insulin. As Shibayagi’s kit recognizes the common sequences between C-peptide 1 and 2, it can measure total amount of C-peptide.

References to Product

References

  • Guo W, Miao C, Liu S, Qiu Z, Li J, Duan E. Efficient differentiation of insulin-producing cells from skin-derived stem cells. Cell Prolif. 2009 Feb;42 (1):49-62
  • Hori Y, Fukumoto M, Kuroda Y. Enrichment of putative pancreatic progenitor cells from mice by sorting for prominin1 (CD133) and platelet-derived growth factor receptor beta. Stem Cells. 2008 Nov;26 (11):2912-20
  • Ibii T, Shimada H, Miura S, Fukuma E, Sato H, Iwata H. Possibility of insulin-producing cells derived from mouse embryonic stem cells for diabetes treatment. J Biosci Bioeng. 2007 Feb;103 (2):140-6
  • Liu MJ, Shin S, Li N, Shigihara T, Lee YS, Yoon JW, Jun HS. Prolonged remission of diabetes by regeneration of beta cells in diabetic mice treated with recombinant adenoviral vector expressing glucagon-like peptide-1. Mol Ther. 2007 Jan;15 (1):86-93
  • Narushima M, Kobayashi N, Okitsu T, Tanaka Y, Li SA, Chen Y, Miki A, Tanaka K, Nakaji S, Takei K, Gutierrez AS, Rivas-Carrillo JD, Navarro-Alvarez N, Jun HS, Westerman KA, Noguchi H, Lakey JR, Leboulch P, Tanaka N, Yoon JW. A human beta-cell line for transplantation therapy to control type 1 diabetes. Nat Biotechnol. 2005 Oct;23 (10):1274-82
  • Torisu T, Sato N, Yoshiga D, Kobayashi T, Yoshioka T, Mori H, Iida M, Yoshimura A. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells. 2007 Feb;12 (2):143-54
References to Summary

References to C-Peptide

  • Beischer W, Heinze E, Keller L, Raptis S, Kerner W, Pfeiffer EF. Human C-peptide. Part II: Clinical studies. Klin Wochenschr. 1976 Aug 1;54 (15):717-25
  • Beischer W, Keller L, Maas M, Scherfer E, Pfeiffer EF. Human C-peptide. Part I: Radioimmunoassay. Klin Wochenschr. 1976 Aug 1;54 (15):709-15
  • Blix PM, Boddie-Willis C, Landau RL, Rochman H, Rubenstein AH. Urinary C-peptide: an indicator of beta-cell secretion under different metabolic conditions. J Clin Endocrinol Metab. 1982 Mar;54 (3):574-80
  • Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci. 1984;19 (4):297-352
  • Conget I, Gonzalez-Clemente JM, Casals E, Casamitjana R, Gomis R, Malaisse WJ. Effect of hyperlipacidemia on plasma C-peptide concentration during euglycemic hyperinsulinemic clamp. Diabetes Res. 1993;22 (1):41-8
  • Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 1975 Jun;55 (6):1278-83
  • Krew MA, Kehl RJ, Thomas A, Catalano PM. Relation of amniotic fluid C-peptide levels to neonatal body composition. Obstet Gynecol. 1994 Jul;84 (1):96-100
  • Rendell M. C-peptide levels as a criterion in treatment of maturity-onset diabetes. J Clin Endocrinol Metab. 1983 Dec;57 (6):1198-206
  • Rubenstein AH, Steiner DF, Horwitz DL, Mako ME, Block MB, Starr JI, Kuzuya H, Melani F. Clinical significance of circulating proinsulin and C-peptide. Recent Prog Horm Res. 1976;33:435-75
  • Tropeano G, Lucisano A, Liberale I, Barini A, Vuolo IP, Martino G, Menini E, Dell'Acqua S. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 1994 Feb;78 (2):305-9
Related Products Documents